Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 7/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366490 | 1.00 | SLC18A3 (0.47) | SLC18A3SIGMAR1CYP11B2CYP2D6TRPA1 | |
| SCHEMBL206905 | 0.91 | SLC18A3 (0.54) | SLC18A3SIGMAR1CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL240786 | 0.83 | SLC18A3 (0.42) | SLC18A3SIGMAR1CYP11B2CYP2D6TRPA1 | |
| SCHEMBL2303598 | 0.83 | SLC18A3 (0.42) | SLC18A3SIGMAR1CYP11B2CYP2D6TRPA1 | |
| SCHEMBL5544343 | 0.80 | HTR3A (0.47) | SLC18A3CYP1A2CYP2C9TSHR | |
| SCHEMBL42580 | 0.79 | SLC18A3 (0.61) | SLC18A3SIGMAR1CYP11B2CYP2D6TRPA1 | |
| SCHEMBL2050 | 0.79 | SLC18A3 (0.61) | SLC18A3SIGMAR1CYP2D6TRPA1CYP2C19 | |
| SCHEMBL1367144 | 0.78 | SLC18A3 (0.45) | SLC18A3SIGMAR1TRPA1 | |
| SCHEMBL1366116 | 0.78 | SLC18A3 (0.45) | SLC18A3SIGMAR1TRPA1 | |
| SCHEMBL242194 | 0.78 | SLC18A3 (0.45) | SLC18A3SIGMAR1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | claimed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | SLC18A3 1403/4885SIGMAR1 1699/4885CYP11B2 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.